A 12-week, Randomized, Double-masked, Parallel Group Comparison of Evening Dosing With Xalacom in Subjects With Glaucoma

NCT00277498 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

528

Enrollment

INDUSTRY

Sponsor class

Conditions

Open Angle Glaucoma
Ocular Hypertension

Interventions

DRUG: Xalacom
DRUG: Xalatan
DRUG: Timolol

Sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.